Adenovirus gene therapy vehicle and cell line

Details Adenovirus gene therapy vehicle and cell line Adenovirus gene therapy vehicle and cell line

1995-10-27

2001-08-28

Nguyen, Dave Trong (Department: 1633)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S320100, C435S455000, C435S091400

Reexamination Certificate

active

06281010

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to the field of somatic gene therapy and the treatment of genetic disorders.
BACKGROUND OF THE INVENTION
Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a therapeutic or reporter transgene to a variety of cell types. Human adenoviruses are comprised of a linear, approximately 36 kb double-stranded DNA genome, which is divided into 100 map units (m.u.), each of which is 360 bp in length. The DNA contains short inverted terminal repeats (ITR) at each end of the genome that are required for viral DNA replication. The gene products are organized into early (E1 through E4) and late (L1 through L5) regions, based on expression before or after the initiation of viral DNA synthesis [see, e.g., M. S. Horwitz et al, “Adenoviridae and Their Replication”,
Virology
, second edition, pp. 1712, ed. B. N. Fields et al, Raven Press Ltd., New York (1990)]. The adenoviruses types 2 and 5 (Ad2 and Ad5, respectively), are not associated with human malignancies.
Recombinant adenoviruses are capable of providing extremely high levels of transgene delivery to virtually all cell types, regardless of the mitotic state. The efficacy of this system in delivering a therapeutic transgene in vivo that complements a genetic imbalance has been demonstrated in animal models of various disorders [K. F. Kozarsky et al,
Somatic Cell Mol. Genet
., 19:449-458 (1993) (“Kozarsky et al I”); K. F. Kozarsky et al,
J. Biol. Chem
., 269:13695-13702 (1994) (“Kozarsky et al II); Y. Watanabe,
Atherosclerosis
, 36:261-268 (1986); K. Tanzawa et al,
FEBS Letters
, 118(1):81-84 (1980); J. L. Golasten et al,
New Engl. J. Med
., 309(11983):288-296 (1983); S. Ishibashi et al,
J. Clin. Invest
., 92:883-893 (1993); and S. Ishibashi et al,
J. Clin. Invest
., 93:1885-1893 (1994)]. The use of recombinant adenoviruses in the transduction of genes into hepatocytes in vivo has previously been demonstrated in rodents and rabbits [see, e.g., Kozarsky II, cited above, and S. Ishibashi et al,
J. Clin. Invest
., 92:883-893 (1993)].
The first-generation recombinant, replication-deficient adenoviruses which have been developed for gene therapy contain deletions of the entire E1a and part of the E1b regions. This replication-defective virus is grown on an adenovirus-transformed, complementation human embryonic kidney cell line containing a functional adenovirus E1a gene which provides a transacting E1a protein, the 293 cell [ATCC CRL1573]. E1-deleted viruses are capable of replicating and producing infectious virus in the 293 cells, which provide E1a and E1b region gene products in trans. The resulting virus is capable of infecting many cell types and can express the introduced gene (providing it carries its own promoter), but cannot replicate in a cell that does not carry the E1 region DNA unless the cell is infected at a very high multiplicity of infection.
However, in vivo studies revealed transgene expression in these E1 deleted vectors was transient and invariably associated with the development of severe inflammation at the site of vector targeting [S. Ishibashi et al,
J. Clin. Invest
., 93:1885-1893 (1994); J. M. Wilson et al,
Proc. Natl. Acad. Sci., USA
, 85:4421-4424 (1988); J. M. Wilson et al,
Clin. Bio
., 3:21-26 (1991); M. Grossman et al,
Som. Cell. and Mol. Gen
., 17:601-607 (1991)]. Antigenic targets for immune mediated clearance are viral proteins expressed from the recombinant viral genome and/or the product of the transgene [Y. Yang et al,
Proc. Natl. Acad. Sci., USA
, 91:4407-4411 (May 1994); Y. Yang et al,
Immun
., 1:433-442 (August 1994)].
There remains a need in the art for additional recombinant adenoviruses, therapeutic compositions and methods which enable effective treatment of disorders and diseases by gene therapy.
SUMMARY OF THE INVENTION
In one aspect of this invention, a novel packaging cell line is provided which expresses adenovirus genes E1a, E1b and E4, or functional fragments thereof. In one embodiment, the E4 gene fragment is open reading frame (ORF) 6 under the control of an inducible promoter.
In another aspect, the invention provides a recombinant adenovirus comprising the DNA of, or corresponding to, at least a portion of the genome of an adenovirus having functional deletions of the E1 and E4 gene regions; a suitable gene operatively linked to regulatory sequences directing its expression, and an adenovirus capsid, the recombinant virus capable of infecting a mammalian cell and expressing the gene product in the cell in vivo or in vitro. In a preferred embodiment, the cell is a muscle cell.
In another aspect, the invention provides a mammalian cell infected with the recombinant virus described above.
In still another aspect, the invention provides a recombinant adenovirus shuttle vector comprising the DNA of, or corresponding to, at least a portion of the genome of an adenovirus having functional deletions of the E1 and E4 gene regions; a suitable gene operatively linked to regulatory sequences capable of directing its expression; and plasmid sequences.
In still a further aspect, the invention provides a method for delivering and stably integrating a selected gene into a mammalian cell comprising introducing into said cell an effective amount of a recombinant virus described above.
In another aspect, the invention provides a method for producing the above-described recombinant Ad virus by co-transfecting the shuttle vector described above and a helper adenovirus into the packaging cell line described above, wherein the transfected cell generates the recombinant adenovirus. The recombinant adenovirus is subsequently isolated and purified therefrom.
Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.


REFERENCES:
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: 5252479 (1993-10-01), Srivasta
patent: 5354678 (1994-10-01), Lebkowski
patent: 5543328 (1996-08-01), McClelland
patent: 5707798 (1998-01-01), Brann
patent: 5756283 (1998-05-01), Wilson et al.
patent: 5776502 (1998-07-01), Foulkes et al.
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5872005 (1999-02-01), Wang et al.
patent: 5928944 (1999-07-01), Seth et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 5994106 (1999-11-01), Kovesdi et al.
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 2790292 (1993-04-01), None
patent: WO93/19191 (1993-09-01), None
patent: WO94/12649 (1994-06-01), None
patent: WO94/26914 (1994-11-01), None
patent: WO94/28152 (1994-12-01), None
patent: WO94/28938 (1994-12-01), None
patent: WO95/00655 (1995-01-01), None
patent: WO95/02697 (1995-01-01), None
patent: WO95/06743 (1995-03-01), None
patent: WO95/10623 (1995-04-01), None
patent: WO95/20671 (1995-08-01), None
patent: WO95/27071 (1995-10-01), None
patent: WO95/34671 (1995-12-01), None
patent: WO96/12030 (1996-04-01), None
patent: WO96/14061 (1996-05-01), None
patent: WO96/13596 (1996-05-01), None
patent: WO96/13598 (1996-05-01), None
patent: WO96/13597 (1996-05-01), None
patent: WO96/18418 (1996-06-01), None
patent: WO96/22378 (1996-07-01), None
Stefan Kafsson (1994) Blood, vol. 78, No. 10: pp. 2481-2492.*
Dong et al. (1996) Human Gene Therapy 7: 319-331.*
Scaria et al. (Jun. 28, 1995) Gene Therapy 2; 295-298.*
Ronald Crystal (1995) Science, vol. 270; pp. 404-409.*
Coghlan (Nov. 25, 1995) New Scientist pp:15-16.*
Marshall (Aug. 1995) Science, vol. 269, pp:1050-1055.*
Marshall (Dec. 1995) Science, vol. 270, pp: 1751.*
Onlzin & Motulsky (Dec. 7, 1995) NIH Report on Gene Therapy.*
Ohman et al. (1993) Virology 194, pp. 50-58.*
Wilson et al. (1994) Hum. Gene. Ther. 5: 501-519.*
Armentano et al. (Oct. 9, 1995) Hum. Gene. Ther. 6: 1343-1353.*
Bridge et al (1993) Virology 193: pp 794-801.*
Bakner (1992) Current Topics in Microbiology and Immunology, vol. 158 pp. 39-66.*
Weinberg et al (1983) Proc. Natl. Acad. Sci. USA, vol. 80, pp: 5383-5386.*
Hirt et al., Methods in Cell Biology, 1994, vol. 43:247-26

Affiliated with

Also associated with

Rating

Adenovirus gene therapy vehicle and cell line does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adenovirus gene therapy vehicle and cell line, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenovirus gene therapy vehicle and cell line will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2552002